Genmab A/S (GMAB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Genmab A/S (GMAB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

21.62

-0.10 (-0.46%)

At close: Jan 14, 2025, 3:59 PM

20.89

-3.38%

Pre-market Jan 15, 2025, 06:10 AM EST

undefined% (undefined)

Bid	20.67
Market Cap	13.73B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.98
PE Ratio (ttm)	22.06
Forward PE	n/a
Analyst	Buy

Ask	20.71
Volume	794,560
Avg. Volume (20D)	1,242,703
Open	22.00
Previous Close	21.72
Day's Range	21.59 - 22.08
52-Week Range	19.85 - 31.88
Beta	undefined

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2009

Employees 2,635

Stock Exchange NASDAQ

Ticker Symbol GMAB

Website https://www.genmab.com

Analyst Forecast

According to 7 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 126.64% from the latest price.

Buy 71.43%

Hold 28.57%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Genmab A/S is scheduled to release its earnings on Feb 12, 2025, during market hours.
Analysts project revenue of $886.73M, reflecting a 31.36% YoY growth and earnings per share of 0.39, making a 8.33% increase YoY.

Why Price Moved

4 months ago · Source

-2.02%

Genmab shares are trading lower after JP Morgan do... Unlock content with Pro Subscription

9 months ago · Source

+1.19%

Genmab shares are trading higher. The company announced it will acquire ProfoundBio for $1.8 billion in cash.

News

22 hours ago · zacks.com

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know

Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 day ago · zacks.com

Are Investors Undervaluing Genmab (GMAB) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

1 month ago · businesswire.com

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody adm...

1 month ago · businesswire.com

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rat...

1 month ago · seekingalpha.com

Genmab Is Too Attractive To Ignore

Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily...

1 month ago · businesswire.com

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free surviv...

1 month ago · proactiveinvestors.co.uk

Scancell strikes deal worth up to $630m with Genmab

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish ...

2 months ago · seekingalpha.com

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith ...

2 months ago · seekingalpha.com

Genmab: Looking To Manage My Position Around Q3 Earnings

Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The com...

2 months ago · businesswire.com

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin'...

3 months ago · zacks.com

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.

3 months ago · zacks.com

Is Genmab (GMAB) Stock Undervalued Right Now?